中国医药
中國醫藥
중국의약
CHINA MEDICINE
2015年
2期
177-179
,共3页
陶林辉%管敏昌%彭苍骄%金小红
陶林輝%管敏昌%彭蒼驕%金小紅
도림휘%관민창%팽창교%금소홍
呼吸道感染%小儿氨酚黄那敏颗粒%利巴韦林%治疗结果
呼吸道感染%小兒氨酚黃那敏顆粒%利巴韋林%治療結果
호흡도감염%소인안분황나민과립%리파위림%치료결과
Respiratory tract infections%Pediatric paracetamol%Ribavirin%Treatment outcome
目的 探讨小儿氨酚黄那敏颗粒联合利巴韦林气雾剂治疗急性上呼吸道感染的疗效.方法 选择浙江省台州市立医院儿科门诊确诊为急性上呼吸道感染患儿138例,按就诊顺序奇偶数分为治疗组和对照组,各69例.对照组口服利巴韦林颗粒,10～15 mg/(kg·d),分3～4次,连用3d.治疗组口服小儿氨酚黄那敏颗粒,1～3岁0.5 ～1包,3次/d,4～6岁1～1.5包,3次/d,7～9岁1.5～2包,3次/d;同时给予利巴韦林气雾剂,首次使用1h内喷4次,1次2～3揿,以后每隔1h喷1次,1次2～3揿,2d以后4次/d,1次2～3揿,儿童每日平均剂量15 ～ 20 mg,连用3d.比较2组治疗5d后疗效、热退时间、鼻塞缓解时间、流涕缓解时间及咳嗽缓解时间.结果 治疗5d后,治疗组有效率明显高于对照组[95.7％ (66/69)比76.8％ (53/69)],差异有统计学意义(x2=13.80,P＜0.05);治疗组患儿热退时间、鼻塞缓解时间、流涕缓解时间及咳嗽缓解时间均短于对照组[(2.4±0.5)d比(2.9±0.6)d、(2.8±0.7)d比(3.8±0.9)d、(3.2±0.8)d比(3.8±0.9)d、(3.6±1.2)d比(4.9±1.3)d,P＜0.01].治疗期间对照组有1例出现白细胞减少,治疗组未出现不良反应.结论 小儿氨酚黄那敏颗粒联合利巴韦林气雾剂治疗急性上呼吸道感染疗效确切.
目的 探討小兒氨酚黃那敏顆粒聯閤利巴韋林氣霧劑治療急性上呼吸道感染的療效.方法 選擇浙江省檯州市立醫院兒科門診確診為急性上呼吸道感染患兒138例,按就診順序奇偶數分為治療組和對照組,各69例.對照組口服利巴韋林顆粒,10～15 mg/(kg·d),分3～4次,連用3d.治療組口服小兒氨酚黃那敏顆粒,1～3歲0.5 ～1包,3次/d,4～6歲1～1.5包,3次/d,7～9歲1.5～2包,3次/d;同時給予利巴韋林氣霧劑,首次使用1h內噴4次,1次2～3撳,以後每隔1h噴1次,1次2～3撳,2d以後4次/d,1次2～3撳,兒童每日平均劑量15 ～ 20 mg,連用3d.比較2組治療5d後療效、熱退時間、鼻塞緩解時間、流涕緩解時間及咳嗽緩解時間.結果 治療5d後,治療組有效率明顯高于對照組[95.7％ (66/69)比76.8％ (53/69)],差異有統計學意義(x2=13.80,P＜0.05);治療組患兒熱退時間、鼻塞緩解時間、流涕緩解時間及咳嗽緩解時間均短于對照組[(2.4±0.5)d比(2.9±0.6)d、(2.8±0.7)d比(3.8±0.9)d、(3.2±0.8)d比(3.8±0.9)d、(3.6±1.2)d比(4.9±1.3)d,P＜0.01].治療期間對照組有1例齣現白細胞減少,治療組未齣現不良反應.結論 小兒氨酚黃那敏顆粒聯閤利巴韋林氣霧劑治療急性上呼吸道感染療效確切.
목적 탐토소인안분황나민과립연합리파위림기무제치료급성상호흡도감염적료효.방법 선택절강성태주시립의원인과문진학진위급성상호흡도감염환인138례,안취진순서기우수분위치료조화대조조,각69례.대조조구복리파위림과립,10～15 mg/(kg·d),분3～4차,련용3d.치료조구복소인안분황나민과립,1～3세0.5 ～1포,3차/d,4～6세1～1.5포,3차/d,7～9세1.5～2포,3차/d;동시급여리파위림기무제,수차사용1h내분4차,1차2～3흠,이후매격1h분1차,1차2～3흠,2d이후4차/d,1차2～3흠,인동매일평균제량15 ～ 20 mg,련용3d.비교2조치료5d후료효、열퇴시간、비새완해시간、류체완해시간급해수완해시간.결과 치료5d후,치료조유효솔명현고우대조조[95.7％ (66/69)비76.8％ (53/69)],차이유통계학의의(x2=13.80,P＜0.05);치료조환인열퇴시간、비새완해시간、류체완해시간급해수완해시간균단우대조조[(2.4±0.5)d비(2.9±0.6)d、(2.8±0.7)d비(3.8±0.9)d、(3.2±0.8)d비(3.8±0.9)d、(3.6±1.2)d비(4.9±1.3)d,P＜0.01].치료기간대조조유1례출현백세포감소,치료조미출현불량반응.결론 소인안분황나민과립연합리파위림기무제치료급성상호흡도감염료효학절.
Objective To explore the therapeutic efficacy of pediatric paracetamol combined with ribavirin aerosol in children with acute upper respiratory tract infection.Methods One hundred and thirty-eight children with acute upper respiratory tract infection were divided into control group (69 cases) and the treatment group (69 cases).Patients in control group were given ribavirin granules.Patients in treatment group were given pediatric paracetamol.Thetherapeutic effects in both groups were evaluated after 5 days.Results After treatment,the effective rate of the treatment group was significantly higher than that of the control group [95.7％ (66/69) vs 76.8％ (53/69)],there was a statistically significant difference (x2 =13.80,P ＜ 0.05).After treatment,the fever lasting time,runny nose relief time,stuffy nose remission time and cough relief time in the treatment group were shorter than those in the control group[(2.4±0.5)d vs (2.9 ±0.6)d,(2.8 ±0.7)d vs (3.8 ±0.9)d,(3.2 ± 0.8) d vs (3.8 ± 0.9) d,(3.6 ± 1.2) d vs (4.9 ± 1.3) d] ; there were statistically significant differences (P ＜ 0.01).During the treatment,the control group had 1 cases of leukopenia and the treatment group had no adverse reactions.Conclusion Pediatric paracetamol combined with ribavirin aerosol are effective in the treatment of acute upper respiratory tract infection in children.
